Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05538572 · ClinicalTrials.gov registry record · Phase 1
A Study of PRT3645 in Participants With Select Advanced or Metastatic Solid Tumors
A Phase 1 study, sponsored by Prelude Therapeutics.
- Completed
- Registry status
- Phase 1
- Development phase
- 22
- Enrollment target
NCT05538572 is a Phase 1 study that has completed, run by Prelude Therapeutics. The registered enrollment target is 22 participants.
The verdict
NCT05538572, a Phase 1 study, has completed, sponsored by Prelude Therapeutics.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 22 participants
- Enrollment target
Study Summary
This is a Phase 1 dose-escalation study of PRT3645, a Cyclin-dependent Kinase 4/6 (CDK4/6) inhibitor, in patients with advanced or metastatic solid tumors. The purpose of this study is to investigate the safety, tolerability, dose limiting toxicity, and to determine maximally tolerated dose and recommended phase 2 dose to be used in subsequent development of PRT3645.
Interventions
- DRUG PRT3645
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 22 participants |
| Start Date | 2022-12-27 |
| Est. Completion | 2024-06-26 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05538572
The ClinicalTrials.gov registry entry for NCT05538572 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 22 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Prelude Therapeutics, which has 12 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which PRT3645 is the first listed.
NCT05538572 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05538572 about?
NCT05538572 is a clinical study titled "A Study of PRT3645 in Participants With Select Advanced or Metastatic Solid Tumors". This is a Phase 1 dose-escalation study of PRT3645, a Cyclin-dependent Kinase 4/6 (CDK4/6) inhibitor, in patients with advanced or metastatic solid tumors. The purpose of this study is to investigate the safety, tolerability, dose limiting toxicity, and to determine maximally tolerated dose and reco...
What is the current status of trial NCT05538572?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 22 participants. The study started on 2022-12-27. Estimated completion is 2024-06-26.
What interventions are being tested in trial NCT05538572?
The interventions under investigation include: PRT3645 (DRUG).
Who is sponsoring clinical trial NCT05538572?
This trial is sponsored by Prelude Therapeutics, which has 12 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.